Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review

被引:2
作者
Seth, Ishith [1 ,2 ,3 ,4 ,5 ]
Siu, Adrian [1 ,3 ,4 ]
Hewitt, Lyndel [1 ,2 ,3 ]
Budak, Ulvi [1 ]
Farah, Beshoy [1 ]
Jaber, Mouhannad [1 ]
机构
[1] Wollongong Hosp, Illawarra Shoalhaven Local Hlth Dist, Wollongong, NSW 2500, Australia
[2] Illawarra Hlth & Med Res Inst, Wollongong, NSW 2522, Australia
[3] Univ Wollongong, Fac Sci Med & Hlth, Wollongong, NSW 2522, Australia
[4] Univ Wollongong, Sch Med, Grad Med, Wollongong, NSW 2522, Australia
[5] Monash Univ, Fac Med & Hlth Sci, South Melbourne, Vic 3004, Australia
关键词
Hepatocellular carcinoma; HCC; Cancer; Liver; Clinical guidelines; Guidelines; SURGICAL RESECTION; RADIOFREQUENCY ABLATION; IMAGING DIAGNOSIS; MULTIDETECTOR CT; LIVER; OUTCOMES; RECOMMENDATIONS; EPIDEMIOLOGY; SURVEILLANCE; CRITERIA;
D O I
10.1007/s12029-023-00961-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundHepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia. The absence of a consensus clinical practice guideline (CPG) specific to HCC management poses challenges in reducing morbidity, mortality, and improving patient recovery. This systematic review aims to evaluate the existing evidence and assess the potential of published guidelines, including those with an international scope, to provide guidance for healthcare professionals in Australia.MethodsElectronic search of MEDLINE, Embase, Cochrane Library, Google Scholar, and PubMed was conducted. Peer-reviewed English language articles from 2005 to June 2022 were included if they described management of HCC as part of an evidence-based overall management plan or CPG. The quality of the included CPGs was assessed by the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool.ResultsTwenty-one articles from 16 regions throughout the world were included in this review. All included guidelines (n = 21, 100%) recommended evaluating cirrhosis, hepatitis B, and hepatitis C as potential risk factors of HCC. Obesity and non-alcoholic fatty liver disease were recommended by 19 CPGs (91%) as risk factor for HCC. Fourteen guidelines (67%) endorsed using the BCLC staging system. Eighteen guidelines (86%) recommended a multidisciplinary approach for the management of HCC. Eighteen guidelines (86%) advised that surveillance using ultrasound should be implemented in all cirrhotic patients every 6 months regardless of the cause of cirrhosis. AGREE II mean overall assessment score was 90% indicating that all guidelines included were highly recommended in majority of domains.ConclusionsThe included CPGs provided a comprehensive approach, emphasizing the evaluation of risk factors, utilization of the BCLC staging system, and the importance of a multidisciplinary approach. Regular surveillance using ultrasound for cirrhotic patients was widely recommended. An understanding of contemporary international CPGs can prioritize aspects of the management of HCC to assist healthcare professionals to develop a national guideline to enable standardized, comprehensive, and evidence-based care for patients with HCC.
引用
收藏
页码:318 / 331
页数:14
相关论文
共 53 条
[1]   Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines [J].
Abdo, Ayman A. ;
Hassanainh, Mazen ;
AlJumah, AbdulRahman ;
Al Olayan, Ashwaq ;
Sanai, Faisal M. ;
Al Alsuhaibani, Hamad ;
AbdulKareem, Huda ;
Abdallah, Khalid ;
AlMuaikeel, Mohammad ;
Al Saghier, Mohammad ;
Babatin, Mohammad ;
Kabbani, Monther ;
Bazarbashi, Shouki ;
Metrakos, Peter ;
Bruix, Jordi .
ANNALS OF SAUDI MEDICINE, 2012, 32 (02) :174-199
[2]  
Bhan I, 2019, MOL TRANSL MED, P125, DOI 10.1007/978-3-030-21540-8_7
[3]   Epidemiology of primary liver cancer [J].
Bosch, FX ;
Ribes, J ;
Borràs, J .
SEMINARS IN LIVER DISEASE, 1999, 19 (03) :271-285
[4]   Hepatocellular carcinoma epidemiology [J].
Bosetti, Cristina ;
Turati, Federica ;
La Vecchia, Carlo .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2014, 28 (05) :753-770
[5]   AGREE II: advancing guideline development, reporting and evaluation in health care [J].
Brouwers, Melissa C. ;
Kho, Michelle E. ;
Browman, George P. ;
Burgers, Jako S. ;
Cluzeau, Francoise ;
Feder, Gene ;
Fervers, Beatrice ;
Graham, Ian D. ;
Grimshaw, Jeremy ;
Hanna, Steven E. ;
Littlejohns, Peter ;
Makarski, Julie ;
Zitzelsberger, Louise .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (18) :E839-E842
[6]   Comparison of Portal Venous and Delayed Phases of Gadolinium-Enhanced Magnetic Resonance Imaging Study of Cirrhotic Liver for the Detection of Contrast Washout of Hypervascular Hepatocellular Carcinoma [J].
Cereser, Lorenzo ;
Furlan, Alessandro ;
Bagatto, Daniele ;
Girometti, Rossano ;
Como, Giuseppe ;
Avellini, Claudio ;
Orsaria, Maria ;
Zuiani, Chiara ;
Bazzocchi, Massimo .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2010, 34 (05) :706-711
[7]  
CHAGAS Aline Lopes, 2020, Arq. Gastroenterol., V57, P1, DOI [10.1590/s0004-2803.202000000-20, 10.1590/S0004-2803.202000000-20]
[8]   Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JS']JSMO, KSMO, MOS and SSO [J].
Chen, L-T ;
Martinelli, E. ;
Cheng, A-L ;
Pentheroudakis, G. ;
Qin, S. ;
Bhattacharyya, G. S. ;
Ikeda, M. ;
Lim, H-Y ;
Ho, G. F. ;
Choo, S. P. ;
Ren, Z. ;
Malhotra, H. ;
Ueno, M. ;
Ryoo, B-Y ;
Kiang, T. C. ;
Tai, D. ;
Vogel, A. ;
Cervantes, A. ;
Lu, S-N ;
Yen, C-J ;
Huang, Y-H ;
Chen, S-C ;
Hsu, C. ;
Shen, Y-C ;
Tabernero, J. ;
Yen, Y. ;
Hsu, C-H ;
Yoshino, T. ;
Douillard, J-Y .
ANNALS OF ONCOLOGY, 2020, 31 (03) :334-351
[9]   A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma [J].
Chen, MS ;
Li, JQ ;
Zheng, Y ;
Guo, RP ;
Liang, HH ;
Zhang, YQ ;
Lin, XJ ;
Lau, WY .
ANNALS OF SURGERY, 2006, 243 (03) :321-328
[10]  
Chen X, 2021, FRONT ONCOL, P11